Recently, the Aponermin for Injection (Chinese trade name:沙艾特) of Wuhan HITECK biopharmaceutical Co., Ltd. is approved by China NMPA. This drug, plus thalidomide and dexamethasone, is indicated for the treatment of adult patients with relapsed or refractory Multiple Myeloma after two or more systemic therapies.

The Aponermin for Injection is a Circularly Permuted TRAIL, which can bind and activate death receptor 4 (DR4)/death receptor 5 (DR5) on the surface of tumor cells, triggering intracellular Caspase reactions through exogenous cell apoptosis pathways, thereby exerting anti-tumor effects. The marketing of the drug will provide new treatment options for patients.